Author(s):
Balasankar Karavadi, Vinothkumar. C, Premalatha. J
Email(s):
balasankar.bioinfo@sathyabama@ac.in
DOI:
10.5958/0974-360X.2020.00771.4 
Address:
Balasankar Karavadi1*,Vinothkumar. C2, Premalatha. J3
1Department of Biomedical Engineering, Sathyabama Institute of Science and Technology, Chennai, Tamilnadu-600 119.
2Department of Electronics and Instrumentation Engineering, Sathyabama Institute of Science and Technology, Chennai, Tamilnadu-600 119.
3Department of Electronics and Communication Engineering, Sathyabama Institute of Science and Technology, Chennai, Tamilnadu-600 119.
*Corresponding Author
Published In:
Volume - 13,
Issue - 9,
Year - 2020
ABSTRACT:
Recognizing explicit ligands in CGSP14 Strain of streptococcus pneumonia utilizing virtual screening approach alongside the approval of ADMET descriptors. The objective successions were recovered from UniProt database,The homology demonstrating was performed by utilizing Modeler 9v7 which is trailed by confirmation utilizing Ramachandran plot, ligands and their analogs were acquired from Pubchem database,docking proteins and its separate analogs was performed by utilizing Discovery studio. Our Insilco examination delineate that proteins having a more prominent potential to progress toward becoming medication focus in CGSP14 Strain of streptococcus pneumonia and the above ligands having higher dock score might be considered as the potential lead particles for drug discovery.
Cite this article:
Balasankar Karavadi, Vinothkumar. C, Premalatha. J. Different interaction analysis of strain CGSP14 in Streptococcus pneumoniae. Research J. Pharm. and Tech 2020; 13(9):4361-4364. doi: 10.5958/0974-360X.2020.00771.4
Cite(Electronic):
Balasankar Karavadi, Vinothkumar. C, Premalatha. J. Different interaction analysis of strain CGSP14 in Streptococcus pneumoniae. Research J. Pharm. and Tech 2020; 13(9):4361-4364. doi: 10.5958/0974-360X.2020.00771.4 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2020-13-9-59
REFERENCES:
1. Avery OT, MacLeod CM, McCarty M. Studies on the chemical nature of the substance inducing transformation of pneumococcal types. J. Exp. Med. 1944; 79:137-158.
2. Klein DL. Pneumococcal disease and the role of conjugate vaccines. Microb. Drug Resist. 1999; 5:147-157.
3. Shak JR, Ludewick HP, Howery KE, Sakai F, Yi H, Harvey RM et.al. Novel role for the Streptococcus pneumoniae toxin pneumolysin in the assembly of biofilms. MBio. 2013;4:e00655-13.
4. Lanie JA, Wai-Leung NG, Kazmierczak KM, Andrzejewski TM, Davidsen TM, Wayne KJ et.al. Genome Sequence of Avery's Virulent Serotype 2 Strain D39 of Streptococcus pneumonia and Comparison with That of Unencapsulated Laboratory Strain R6. J. Bacteriol. 2007; 189: 38.
5. Tettelin H, Nelson KE, Paulsen IT, Eisen JA, Read TD, Peterson S et al. Complete genome sequence of a virulent isolate of Streptococcus pneumoniae. Science. 2001; 293:498-506.
6. Cardoso TC, Lopes LM, Carneiro AH. A case-control study on risk factors for early-onset respiratory tract infection in patients admitted in ICU. BMC Pulm. Med. 2007; 7:12-17.
7. Dopazo J, Mendoza A, Herrero J, Caldara F, Humbert Y, Friedli L, Guerrier M,Grand-Schenkm E, Gandin C,Annotated draft genomic sequence from aStreptococcus pneumoniae type 19F clinical isolate, Microb.Drug resists, 7, 99-125, 2001.
8. Hava DL, Camilli A, Large-scale identification of serotype 4 Streptococcus pneumoniae virulence factors, Mol.Microbiol., 45, 1389-1406, 2002.
9. Hicks LA, Harrison LH, Flannery B, Hadler JL, Schaffner W, Incidence of pneumococcal disease due to nonpneumococcalconjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7vaccination,1998–2004. J. Infect. Dis. 196, 1346-1354, 2007.
10. Klein DL: Pneumococcal disease and the role of conjugate vaccines. Microbial Drug Resist. 1999, 5: 147-157. 10.1089/mdr.1999.5.147.
11. Plotkin SA, Orenstein W, Offit PA. Vaccines. Philadelphia, PA: Elsevier– Saunders, p. 542-51, 2012.
12. Karavadi B, Suresh MX. Receptor identification and lead molecular discovery of phage encoded protein in TCH8431/19A strain of Streptococcus pneumoniae: A computational approach. Int J Appl Pharm 2014; 6:6-10.
13. Robertson GT, Ng WL, Foley J, Gilmour R, Winkler ME. Global transcriptional analysis of clpP mutations of type 2 Streptococcus pneumoniae and their effects on physiology and virulence. J. Bacteriol. 2002; 184: 3508-3520.
14. Karavadi B, Suresh XM. Homology modeling of polymerase and CPSbiosynthesis proteins in CGSP14 strain of Streptococcus pneumoniaand its ligand identification: An in silico approach. Asian J Pharm Clin Res; 7:162-5, 2014.
15. Kuo LC, Lai CC, Liao Ch, Hsu Ck, Chang YL, Change CY et.al. Multidrug-resistant Acinetobacter baumannii bacteremia: clinical feature, antimicrobial therapy and outcome. Clin. Microbiol. Infect. 2007; 13:196-198.
16. Mondal UK, Sen A, Bothra AK. Homology modeling of the Cytolethaldistending toxin B gene of Helicobacter hepaticus ATCC 51449. International Journal of Interrogative Biology 2010; 10:35-40.
17. Karavadi B, Suresh MX. Homology modelling and molecular drug design approach in identifying drug targets of TIGR4 in Streptococcus pneumonia
18. Rama Thilagam C, Akhilesh Upgade, Anusha Bhaskar, Umarani PR, ManivannanV. Synthesis and molecular docking studies of ethyl 1-benzenesulfonyl -2-[(e)-2-(2 methylphenyl) ethenyl] indole-3-carboxylate with human renin complexed with inhibitor. Asian J Pharm Clin Res. 2013;6:96-99.
19. Laskoswki RA, MacArthur MW, Moss DS, Thorton JM. Procheck: a program to check the stereochemical quality of protein structures. J. Appl. Cryst. 1993; 26:283-291.